# FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

> **NCT00564733** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 55 (actual)

## Conditions studied

- Malignant Pleural Effusion
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel
- **PROCEDURE:** computed tomography
- **PROCEDURE:** positron emission tomography
- **RADIATION:** fludeoxyglucose F 18
- **OTHER:** imaging biomarker analysis

## Key facts

- **NCT ID:** NCT00564733
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-09
- **Final completion:** 2012-03
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00564733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00564733, "FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00564733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*